Literature DB >> 29547875

Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.

Deepak Reddy Gade1, Amareswararao Makkapati2, Rajesh Babu Yarlagadda3, Godefridus J Peters4, B S Sastry5, V V S Rajendra Prasad6.   

Abstract

Overexpression of P-glycoprotein (P-gp) leads to the emergence of multidrug resistance (MDR) in cancer treatment. Acridones have the potential to reverse MDR and sensitize cells. In the present study, we aimed to elucidate the chemosensitization potential of acridones by employing various molecular modelling techniques. Pharmacophore modeling was performed for the dataset of chemosensitizing acridones earlier proved for cytotoxic activity against MCF7 breast cancer cell line. Gaussian-based QSAR studies also performed to predict the favored and disfavored region of the acridone molecules. Molecular dynamics simulations were performed for compound 10 and human P-glycoprotein (obtained from Homology modeling). An efficient pharmacophore containing 2 hydrogen bond acceptors and 3 aromatic rings (AARRR.14) was identified. NCI 2012 chemical database was screened against AARRR.14 CPH and identified 25 best-fit molecules. Potential regions of the compound were identified through Field (Gaussian) based QSAR. Regression analysis of atom-based QSAR resulted in r2 of 0.95 and q2 of 0.72, whereas, regression analysis of field-based QSAR resulted in r2 of 0.92 and q2 of 0.87 along with r2cv as 0.71. The fate of the acridone molecule (compound 10) in the P-glycoprotein environment is analyzed through analyzing the conformational changes occurring during the molecular dynamics simulations. Combined data of different in silico techniques provided basis for deeper understanding of structural and mechanistic insights of interaction phenomenon of acridones with P-glycoprotein and also as strategic basis for designing more potent molecules for anti-cancer and multidrug resistance reversal activities.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D QSAR; Acridones; Molecular dynamics; Multidrug resistance; Pharmacophore modeling; p-Glycoprotein inhibition

Mesh:

Substances:

Year:  2018        PMID: 29547875     DOI: 10.1016/j.compbiolchem.2018.02.014

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  5 in total

1.  SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Megumi Murakami; Sung-Han Hsiao; Te-Chun Liu; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar
Journal:  Cancer Lett       Date:  2018-07-06       Impact factor: 8.679

2.  An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.

Authors:  Xin Xue; Gang Bao; Hai-Qing Zhang; Ning-Yi Zhao; Yuan Sun; Yue Zhang; Xiao-Long Wang
Journal:  Molecules       Date:  2018-12-01       Impact factor: 4.411

3.  Compound Prunetin Induces Cell Death in Gastric Cancer Cell with Potent Anti-Proliferative Properties: In Vitro Assay, Molecular Docking, Dynamics, and ADMET Studies.

Authors:  Preethi Vetrivel; Seong Min Kim; Sang Eun Ha; Hun Hwan Kim; Pritam Bhagwan Bhosale; Kalaiselvi Senthil; Gon Sup Kim
Journal:  Biomolecules       Date:  2020-07-21

4.  3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity.

Authors:  Salimeh Mirzaei; Farzin Hadizadeh; Razieh Ghodsi; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2021-08-24       Impact factor: 3.411

5.  Design and prediction of novel pyrazole derivatives as potential anti-cancer compounds based on 2D-2D-QSAR study against PC-3, B16F10, K562, MDA-MB-231, A2780, ACHN and NUGC cancer cell lines.

Authors:  Fatima Ezzahra Bennani; Latifa Doudach; Khalid Karrouchi; Youssef El Rhayam; Christopher E Rudd; M'hammed Ansar; My El Abbes Faouzi
Journal:  Heliyon       Date:  2022-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.